Drug Trial Radar · NCT04206072
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Last checked: Nov 19, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
362
Actual
Start
Dec 24, 2019
Primary completion
Jul 30, 2022
Study completion Jul 15, 2025
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy and safety of D-0316 versus Icotinib, a standard of care epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with locally advanced or Metastatic Non Small Cell Lung Cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
- EGFR Gene Mutation
Interventions
D-0316 CapsuleDrug
The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment. Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316.
Icotinib Hydrochloride TabletsDrug
Icotinib (125 mg three times daily, orally), treatment should continue until disease progression or meet the withdrawal criteria. A cycle of treatment is defined as 21 days of three times daily treatment. Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Icotinib arm and confirmed T790M mutation positive have the option to receive D-0316 (crossover to active D-0316).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression Free Survival (PFS) assessed by IRCTime frame: From randomization to objective disease progression or death, whichever came first, assessed up to 20 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Liuzhou Workers Hospital
Liuzhou, China
The First Affiliated Hospital of Medical School of Zhejiang University
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.